Side-by-side · Research reference

ACE-031vsTestagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/44 cited

BAnimal-MechanisticHUMAN-REVIEWED11/41 cited

ACE-031

ActRIIB-Fc Fusion · Phase 2 Halted

Phase 2Highest trial stage

2011Development halted

~58.4 kDaMolecular weightReichel 2025

SQ · Weekly dosing investigated

Testagen

Bioregulator Peptide · Khavinson School

Lys-Glu-Asp-GlySequenceFedoreyeva 2011

NuclearLocalizationFedoreyeva 2011

TesticularTissue target

SQ · Abdomen · Cyclical

01Mechanism of Action

Parameter

ACE-031

Testagen

Primary target

Myostatin, GDF11, activin A — TGF-β superfamily ligands

Testicular tissue; proposed nuclear DNA interaction

Pathway

Soluble decoy receptor binds circulating myostatin/TGF-β ligands → prevents ActRIIB activation → SMAD2/3 pathway inhibition

Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011

Downstream effect

Disinhibition of myogenic signaling, increased skeletal muscle mass and strength

Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011

Feedback intact?

—

Unknown — no HPG axis data

Origin

Recombinant fusion protein: human ActRIIB extracellular domain + IgG1-Fc fragmentReichel 2025

Khavinson bioregulator school — isolated from testicular tissue peptide fractions

Antibody development

—

02Dosage Protocols

Parameter

ACE-031

Testagen

Clinical dosing

Weekly or biweekly SQ injections (exact doses undisclosed pre-halt)

Phase 2 DMD trial protocol not fully published.

—

Black market products

Variable purity; 12/14 tested products contained target protein plus contaminantsReichel 2025

SDS-PAGE revealed multiple protein bands; quality control absent.Reichel 2025

—

Evidence basis

Phase 2 trial discontinued — incomplete dataset

Animal mechanistic / in vitro onlyFedoreyeva 2011

Half-life

Days to weeks (Fc-fusion typical kinetics)

IgG1-Fc domain confers extended circulation time.

Unknown — likely minutes (short peptide)

Duration investigated

12–24 weeks (trial cut short)

—

Typical protocol (anecdotal)

—

100–200 mcg / day

No published human dosing studies; derived from Russian bioregulator practice.

Frequency

—

Once daily or alternate days

Cycle length

—

10–20 days on, 10–14 days off

Bioregulator tradition uses pulsed cycles; no controlled data.

Route

—

Subcutaneous

Reconstitution

—

Sterile water or bacteriostatic saline

04Side Effects & Safety

Parameter

ACE-031

Testagen

Epistaxis (nosebleeds)

Significant incidence in Phase 2 DMD trial — primary safety signal

—

Telangiectasia

Dilated capillaries / spider veins observed

—

Vascular abnormalities

Mechanism: ActRIIB/ALK1 pathway disruption affects vascular homeostasis

—

Injection site reactions

Local erythema, induration (biologics class effect)

Erythema, mild irritation (potential)

Antibody development

Potential for anti-drug antibodies (Fc-fusion proteins); incidence not reported

—

Black market contaminants

12/14 tested products contained multiple unidentified proteins alongside ACE-031Reichel 2025

—

Systemic effects

—

Unknown — no human safety data

Hormonal impact

—

No published data on testosterone, LH, FSH effects

Long-term safety

—

Unknown — no long-term studies

Absolute Contraindications

ACE-031

·History of vascular disorders (epistaxis, telangiectasia, HHT)
·Pregnancy (TGF-β pathway critical for fetal development)
·Active malignancy (myostatin inhibition may affect tumour growth)
·Use of non-pharmaceutical grade ACE-031 (contamination risk)Reichel 2025

Testagen

·Active testicular malignancy

Relative Contraindications

ACE-031

·Coagulation disorders or anticoagulant use (epistaxis risk)
·Hereditary hemorrhagic telangiectasia (HHT) family history
·Cardiovascular disease (vascular remodeling effects unknown)

Testagen

·Hormone-sensitive cancers (no data; theoretical caution)
·Pregnant or breastfeeding (no data)

05Administration Protocol

Parameter

ACE-031

Testagen

1. Pharmaceutical status

ACE-031 is not FDA-approved or commercially available. Phase 2 development was discontinued in 2011 due to safety concerns. Any ACE-031 on the black market is unregulated research chemical.

Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.

2. Black market quality

12 of 14 tested black market ACE-031 products contained the target protein but also carried multiple unidentified protein contaminants detectable by SDS-PAGE. Two products contained no ACVR2B-immunoreactive material.Reichel 2025

Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).

3. Detection in sport

ACE-031 is prohibited under WADA S4.3 (Myostatin Inhibitors). Gel electrophoresis and Western blotting using ACVR2B-specific antibodies can detect the ~58.4 kDa protein in biological samples.Reichel 2025

Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.

4. Clinical trial route

Phase 2 protocol used subcutaneous injections at weekly or biweekly intervals. Exact dosing protocols remain unpublished.

Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.

5. Cycle protocol

—

10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.